SynAct Pharma AB SYNACT
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing positions may be maintained while new purchases await clearer phase 3 guidance or a completed Brazil agreement.
The partnership agreement strengthens the dengue opportunity but low cash and phase 3 risks support the continued HOLD signal.
Investors view the partnership agreement as validation of the platform and note improved financial runway.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 4 Nov 2026 — Report shows worsened net income but strengthened cash position post-equity raise, driven by Q3 closing.
About the company
SynAct Pharma develops resomelagon (AP1189), a melanocortin receptor agonist for resolution of inflammation in rheumatoid arthritis and dengue. The company is in late-stage clinical development and pre-revenue.
Bull case
The Hipolabor partnership validates resomelagon's commercial potential and reduces development risk in Brazil.
Bear case
Low cash position and missed primary endpoint in the phase 2b study imply continued high execution risk ahead of phase 3.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Successful phase 3 initiation in RA | Rejection or demand for additional studies delays development and increases funding needs. | Approved phase 3 design enables partnering deals and higher valuation. |
| Final commercial agreement in Brazil | No binding deal reduces validation and upfront revenue. | Binding agreement brings revenue and broadens indication scope. |
Why this signal
The partnership agreement strengthens the dengue opportunity but low cash and phase 3 risks support the continued HOLD signal.
Recent news
SynAct published the Q3 report showing SEK 42.4 million in cash and runway into Q4 2027. BioVal BioStock Analytics initiated coverage valuing three programs at SEK 2.9 billion rNPV. FDA Type C meeting on phase 3 design expected by Q1 2027.